Welcome to our dedicated page for Pacific Biosc news (Ticker: PACB), a resource for investors and traders seeking the latest updates and insights on Pacific Biosc stock.
PacBio (Pacific Biosciences of California, Inc., NASDAQ: PACB) is a life science technology company focused on advanced genetic sequencing, and its news flow reflects developments across genomics research, collaborations, and financial performance. The company regularly issues press releases describing how its HiFi long-read sequencing platforms are being adopted in human health, rare disease research, and other genomics applications.
Recent PacBio news highlights planned collaborations with organizations such as the n-Lorem Foundation and EspeRare to apply long-read whole-genome sequencing in research on individualized antisense oligonucleotide therapies for ultra-rare and nano-rare genetic diseases. Other coverage includes projects where PacBio HiFi sequencing is used as a first-line whole-genome approach in studies of Sudden Unexplained Death in Childhood, and multi-center research through the HiFi Solves Consortium evaluating the clinical research utility of HiFi genomes in complex genomic regions.
Investors and researchers following PACB news will also find updates on technology advances, such as the community-developed CiFi long-read 3C method that integrates chromatin conformation capture with HiFi sequencing, and regulatory milestones achieved through partners like Berry Genomics in China with the Sequel II CNDx system. Financial news includes quarterly and preliminary annual revenue announcements, details on instrument and consumable performance, and commentary on new sequencing chemistries and assay portfolios.
This PACB news page on Stock Titan aggregates these types of announcements so readers can track PacBio’s research collaborations, technology developments, regional partnerships, and earnings-related updates in one place. Users interested in genomic sequencing, long-read technologies, and the business outlook for PacBio can review the latest press releases and historical news items to understand how the company’s platforms are being used and how management describes its progress.
PacBio (NASDAQ: PACB) announced the grant of stock options and restricted stock units (RSUs) to a newly hired employee. The Compensation Committee of PacBio's Board approved non-qualified stock options for 80,000 shares and RSUs for 40,000 shares, effective November 15, 2021. The exercise price for the options is set at $26.70, matching the closing price on the effective date. The options will vest over four years, with partial vesting after one year. This grant is part of the 2020 Inducement Equity Incentive Plan, aimed at attracting new talent to the company.
PacBio (NASDAQ: PACB) has partnered with ARUP Laboratories to improve the diagnostic yield for unexplained rare disease cases through whole genome HiFi sequencing. This collaboration aims to leverage PacBio's Sequel IIe system within the Utah NeoSeq Project, enhancing the detection of variants that short-read sequencing might miss. Currently, diagnostic yield stands at 30%-50%, and the study seeks to increase this by utilizing HiFi sequencing to analyze previously sequenced samples. If successful, HiFi WGS may serve as a frontline diagnostic tool for rare disorders.
PacBio announced the launch of the HiFiViral SARS-CoV-2 Kit, a comprehensive solution for detecting COVID-19 variants. This kit is aimed at enhancing public health laboratories' ability to identify new variants and includes cost-effective sequencing methods that significantly improve workflow efficiency. The kit can process up to 384 samples simultaneously and is designed to reduce hands-on time significantly. Additionally, PacBio is releasing an upgraded HiFi microbial whole genome assembly application, enhancing the capabilities of its existing sequencing systems to aid pathogen surveillance.
PacBio announced participation in two upcoming investor conferences. Executives will present at the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 11:20 am ET, and at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum on November 18, 2021, at 2:00 pm ET. Live webcasts will be available on the company’s investor page, with replays accessible for at least 30 days post-presentation. PacBio specializes in long-read sequencing technology, providing insights into genetic variation.
PacBio (NASDAQ: PACB) reported strong financial results for Q3 2021, with revenue reaching $34.9 million, an 83% year-over-year increase. The company installed 44 Sequel II/IIe systems during the quarter, bringing the total installed base to 326 systems. Gross profit soared to $15.4 million, reflecting a 117% increase and a gross margin of 44%. Despite this growth, operating expenses surged to $89.8 million, influenced by substantial stock-based compensation. Net income stood at $16.5 million, a significant turnaround from the $23.7 million loss in Q3 2020.
PacBio Expands Genetic Testing Services
On November 2, 2021, PacBio announced a partnership with Prenetics Group Limited to enhance genetic screening services, including carrier and cancer-risk screenings across Hong Kong, Southeast Asia, and the UK. Utilizing PacBio’s SMRT HiFi sequencing technology, Prenetics aims to improve accuracy in detecting genetic mutations through its Circle Medical offering. This collaboration is regarded as a significant step in clinical genomics, with potential implications for personalized healthcare.
Pacific Biosciences (NASDAQ: PACB) will conduct its third quarter 2021 financial results conference call on November 2, 2021, at 4:30 PM ET. The call will be available via webcast on the company’s investor relations website. Interested parties can access the call by using the toll-free number 888.366.7247 or the international number 707.287.9330, with Conference ID 5129207. Pacific Biosciences focuses on long-read sequencing technology, empowering researchers in diverse fields such as human biomedical research and microbiology.
Pacific Biosciences (NASDAQ: PACB) announced a partnership with the European Reference Genome Atlas (ERGA) to enhance biodiversity research through high-quality genomic data. The collaboration aims to generate complete, error-free genome assemblies for 200,000 European plant and animal species by 2030, supporting conservation efforts. PacBio's HiFi Sequencing technology ensures reliable genetic mapping. This initiative aligns with PacBio's ongoing commitment to biodiversity genomics and global collaborative projects.
Pacific Biosciences (NASDAQ: PACB) announced on September 24, 2021, that its Compensation Committee granted stock options for 100,000 shares and restricted stock units (RSUs) for 50,000 shares to a new employee. These awards are part of the 2020 Inducement Equity Incentive Plan, introduced to attract new talent. The stock options have an exercise price of $27.99, equal to the stock's closing price on the grant date. The vesting schedule includes milestones at one year and monthly thereafter for options, while RSUs vest over four years.
Pacific Biosciences (PACB) has completed its acquisition of Omniome, enhancing its position in the sequencing market by combining long-read and short-read technologies. This acquisition is expected to accelerate the adoption of PacBio’s SMRT Sequencing platform, allowing for increased accuracy and sensitivity in clinical applications. The transaction, valued at approximately $316 million in cash and stock, is supported by a $300 million private placement financing. The integration aims to unlock new markets and improve cancer diagnostics.